| Literature DB >> 29986520 |
Loren Pickart1, Anna Margolina2.
Abstract
The human peptide GHK (glycyl-l-histidyl-l-lysine) has multiple biological actions, all of which, according to our current knowledge, appear to be health positive. It stimulates blood vessel and nerve outgrowth, increases collagen, elastin, and glycosaminoglycan synthesis, as well as supports the function of dermal fibroblasts. GHK’s ability to improve tissue repair has been demonstrated for skin, lung connective tissue, boney tissue, liver, and stomach lining. GHK has also been found to possess powerful cell protective actions, such as multiple anti-cancer activities and anti-inflammatory actions, lung protection and restoration of chronic obstructive pulmonary disease (COPD) fibroblasts, suppression of molecules thought to accelerate the diseases of aging such as NFκB, anti-anxiety, anti-pain and anti-aggression activities, DNA repair, and activation of cell cleansing via the proteasome system. Recent genetic data may explain such diverse protective and healing actions of one molecule, revealing multiple biochemical pathways regulated by GHK.Entities:
Keywords: COPD; GHK; GHK-Cu; anti-oxidant; fibrinogen; gene profiling; skin regeneration; wound healing
Mesh:
Substances:
Year: 2018 PMID: 29986520 PMCID: PMC6073405 DOI: 10.3390/ijms19071987
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Estimate of number of genes affected by glycyl-l-histidyl-l-lysine (GHK) [5].
| Percent Change | Genes Stimulated | Genes Suppressed |
|---|---|---|
| 50–99% | 1569 | 583 |
| 100–199% | 646 | 469 |
| 200–299% | 227 | 196 |
| 300–599% | 196 | 207 |
| 600–899% | 39 | 47 |
| 900–1199% | 8 | 7 |
| 1200% or more | 2 | 4 |
Genes Relevant to Neurons’ Function upregulated and downregulated by GHK.
| Gene Title and Abbreviation (The GENE Database) | Percent Change |
|---|---|
| OPRM1, 1 opioid receptor, mu 1 | +1294 |
| TP73, 2 tumor protein p73 | +938 |
| KCND1, 3 potassium voltage-gated channel, Shal-related subfamily, member 1 | +845 |
| SLC8A2, 4 solute carrier family 8 (sodium/calcium exchanger), member 2 | +737 |
| CNTNAP2, 5 contactin associated protein-like 2 | +581 |
| STMN3, 6 stathmin-like 3 | +500 |
| LPHN3, 7 latrophilin 3 | +494 |
| ANGPT1, 8 angiopoietin 1 | +487 |
| SYN3, 9 synapsin III | +478 |
| DPP6,10 dipeptidyl-peptidase 6 | +448 |
| PITX3, 221 paired-like homeodomain 3 | −541 |
| NOTCH3, 222 notch 3 | −547 |
| DLGAP1, 223 discs, large homolog-associated protein 1 | −547 |
| SLIT1, 224 slit homolog 1 | −553 |
| BSN, 225 bassoon (presynaptic cytomatrix protein) | −563 |
| CELSR1, 226 cadherin, EGF LAG seven-pass G-type receptor 1 | −647 |
| CACNB4, 227 calcium channel, voltage-dependent, beta 4 subunit | −672 |
| NDN, 228 necdin homolog (mouse) | −729 |
| EDNRB, 229 endothelin receptor type B | −768 |
| CHRM2, 230 cholinergic receptor, muscarinic 2 | −1049 |
GHK’s Effect on Gene Expression relevant to the Ubiquitin/Proteasome System [4].
|
|
| |
| 1 | ubiquitin specific peptidase 29, USP29 | +1056 |
| 2 | ubiquitin protein ligase E3 component n-recognin 2, UBR2 | +455 |
| 3 | gamma-aminobutyric acid (GABA) B receptor, GABBR1 | +310 |
| 4 | ubiquitin specific peptidase 34, USP34 | +195 |
| 5 | parkinson protein 2, E3 ubiquitin protein ligase (parkin), PARK2 | +169 |
| 6 | ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast), UBE2I | +150 |
| 7 | ubiquitin protein ligase E3 component n-recognin 4, UBR4 | +146 |
| 8 | ubiquitin protein ligase E3B, UBE3B | +116 |
| 9 | ubiquitin specific peptidase 2, USP2 | +104 |
| 10 | ubiquitin-like modifier activating enzyme 6, UBA6 | +104 |
| 11 | ubiquitination factor E4B (UFD2 homolog, yeast), UBE4B | +99 |
| 12 | ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast), UBE2M | +92 |
| 13 | Ubiquitin-like modifier activating enzyme 7, UBA7 | +88 |
| 14 | HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1, HECW1 | +81 |
| 15 | proteasome (prosome, macropain) 26S subunit, ATPase, 3, PSMC3 | +81 |
| 16 | ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast), UBE2D1 | +79 |
| 17 | proteasome (prosome, macropain) subunit, beta type, 2, PSMB2 | +79 |
| 18 | ubiquitin protein ligase E3 component n-recognin 5, UBR5 | +77 |
| 19 | ubiquitin specific peptidase 21, USP21 | +76 |
| 20 | OTU domain, ubiquitin aldehyde binding 2, OTUB2 | +76 |
| 21 | proteasome (prosome, macropain) inhibitor subunit 1 (PI31), PSMF1 | +75 |
| 22 | ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast), UBE2H | +73 |
| 23 | ubiquitin-conjugating enzyme E2N (UBC13 homolog, yeast), UBE2N | +72 |
| 24 | ubiquitin carboxyl-terminal hydrolase L5, UCHL5 | +71 |
| 25 | ubiquitin specific peptidase 6 (Tre-2 oncogene) pseudogene, LOC220594 | +71 |
| 26 | proteasome (prosome, macropain) 26S subunit, non-ATPase, 13, PSMD13 | +70 |
| 27 | ubiquitin associated protein 1, UBAP1 | +70 |
| 28 | ubiquitin-conjugating enzyme E2B (RAD6 homolog), UBE2B | +69 |
| 29 | TMEM189-UBE2V1 readthrough, TMEM189-UBE2V1 | +67 |
| 30 | proteasome (prosome, macropain) 26S subunit, non-ATPase, 1, PSMD1 | +64 |
| 31 | proteasome (prosome, macropain) 26S subunit, non-ATPase, 3, PSMD3 | +64 |
| 32 | ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein, 1 (Drosophila), ARIH1 | +61 |
| 33 | BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase), BAP1 | +60 |
| 34 | ubiquitin interaction motif containing 1, UIMC1 | +60 |
| 35 | ubiquitin associated protein 2-like, UBAP2L | +57 |
| 36 | ubiquitin protein ligase E3 component n-recognin 7 (putative), UBR7 | +56 |
| 37 | ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, yeast), UBE2G1 | +54 |
| 38 | itchy E3 ubiquitin protein ligase homolog (mouse), ITCH | +54 |
| 39 | ubiquitin-conjugating enzyme E2D 4 (putative), UBE2D4 | +51 |
| 40 | proteasome (prosome, macropain) 26S subunit, non-ATPase, 10, PSMD10 | +50 |
| 41 | WW domain containing E3 ubiquitin protein ligase 1, WWP1 | +50 |
| 42 | ubiquitin-like 3, UBL3 | +50 |
|
|
| |
| 1 | ubiquitin associated and SH3 domain containing A, UBASH3A | −89 |
GHK and Genes Associated with Pain [30].
| Gene Abbreviation, Name (GENE Database) | Percent Change | Comment (GENE Database) |
|---|---|---|
| ORPM1, opioid receptor mu 1 | +1294 | the principal target of endogenous opioid peptides such as beta-endorphin and enkephalins. |
| CCKAR, cholecystokinin A receptor | +190 | regulates satiety and the release of beta-endorphin and dopamine. |
| CNR1, cannabinoid receptor 1 | +172 | involved in the cannabinoid-induced CNS effects |
| SIGMAR1, sigma non-opioid intracellular receptor 1 | +155 | a receptor protein that interacts with a variety of psychotomimetic drugs, including cocaine and amphetamines. |
| PNOC, prepronociceptin | +150 | A receptor for proteins involved in regulation of pain sensitivity |
| OXT, oxytocin/neurophysin I prepropeptide | +136 | A precursor protein for oxytocin |
| GRIA3, glutamate ionotropic receptor AMPA type subunit 3 | −126 | Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain |
| OPRK1, opioid receptor kappa 1 | −119 | a receptor for various synthetic opioids |